Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Emergency management of immune-related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes.

Cooksley T, Higham C, Lorigan P, Trainer P.

Cancer. 2018 Oct 23. doi: 10.1002/cncr.31789. [Epub ahead of print] No abstract available.

PMID:
30351448
2.

A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly.

Trainer PJ, Newell-Price JDC, Ayuk J, Aylwin SJB, Rees A, Drake W, Chanson P, Brue T, Webb SM, Fajardo C, Aller J, McCormack AI, Torpy DJ, Tachas G, Atley L, Ryder D, Bidlingmaier M.

Eur J Endocrinol. 2018 Aug;179(2):97-108. doi: 10.1530/EJE-18-0138. Epub 2018 May 22.

3.

Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN.

Valassi E, Feelders R, Maiter D, Chanson P, Yaneva M, Reincke M, Krsek M, Tóth M, Webb SM, Santos A, Paiva I, Komerdus I, Droste M, Tabarin A, Strasburger CJ, Franz H, Trainer PJ, Newell-Price J, Wass JA, Papakokkinou E, Ragnarsson O; ERCUSYN Study Group.

Clin Endocrinol (Oxf). 2018 Jun;88(6):787-798. doi: 10.1111/cen.13600. Epub 2018 Apr 16. Erratum in: Clin Endocrinol (Oxf). 2018 Nov;89(5):678.

PMID:
29574994
4.

Growth Hormone Research Society perspective on biomarkers of GH action in children and adults.

Johannsson G, Bidlingmaier M, Biller BMK, Boguszewski M, Casanueva FF, Chanson P, Clayton PE, Choong CS, Clemmons D, Dattani M, Frystyk J, Ho K, Hoffman AR, Horikawa R, Juul A, Kopchick JJ, Luo X, Neggers S, Netchine I, Olsson DS, Radovick S, Rosenfeld R, Ross RJ, Schilbach K, Solberg P, Strasburger C, Trainer P, Yuen KCJ, Wickstrom K, Jorgensen JOL; Growth Hormone Research Society.

Endocr Connect. 2018 Mar;7(3):R126-R134. doi: 10.1530/EC-18-0047. Epub 2018 Feb 26. Review.

5.

Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN.

Valassi E, Franz H, Brue T, Feelders RA, Netea-Maier R, Tsagarakis S, Webb SM, Yaneva M, Reincke M, Droste M, Komerdus I, Maiter D, Kastelan D, Chanson P, Pfeifer M, Strasburger CJ, Tóth M, Chabre O, Krsek M, Fajardo C, Bolanowski M, Santos A, Trainer PJ, Wass JAH, Tabarin A; ERCUSYN Study Group.

Eur J Endocrinol. 2018 Apr;178(4):399-409. doi: 10.1530/EJE-17-0997. Epub 2018 Feb 12.

PMID:
29440375
6.

A prospective longitudinal study of Pasireotide in Nelson's syndrome.

Daniel E, Debono M, Caunt S, Girio-Fragkoulakis C, Walters SJ, Akker SA, Grossman AB, Trainer PJ, Newell-Price J.

Pituitary. 2018 Jun;21(3):247-255. doi: 10.1007/s11102-017-0853-3.

7.

Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly.

Badia X, Trainer P, Biermasz NR, Tiemensma J, Carreño A, Roset M, Forsythe A, Webb SM.

J Med Econ. 2018 Apr;21(4):382-389. doi: 10.1080/13696998.2017.1419960. Epub 2018 Jan 5.

PMID:
29261359
8.

Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement.

Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, Melmed S, Mortini P, Wass J, Giustina A; Pituitary Society, Expert Group on Pituitary Tumors.

Pituitary. 2017 Oct;20(5):489-498. doi: 10.1007/s11102-017-0838-2. Erratum in: Pituitary. 2018 Sep 20;:.

9.

In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism.

Salvatori R, Radian S, Diekmann Y, Iacovazzo D, David A, Gabrovska P, Grassi G, Bussell AM, Stals K, Weber A, Quinton R, Crowne EC, Corazzini V, Metherell L, Kearney T, Du Plessis D, Sinha AK, Baborie A, Lecoq AL, Chanson P, Ansorge O, Ellard S, Trainer PJ, Balding D, Thomas MG, Korbonits M.

Eur J Endocrinol. 2017 Sep;177(3):257-266. doi: 10.1530/EJE-17-0293. Epub 2017 Jun 20.

10.

Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN.

Valassi E, Franz H, Brue T, Feelders RA, Netea-Maier R, Tsagarakis S, Webb SM, Yaneva M, Reincke M, Droste M, Komerdus I, Maiter D, Kastelan D, Chanson P, Pfeifer M, Strasburger CJ, Tóth M, Chabre O, Tabarin A, Krsek M, Fajardo C, Bolanowski M, Santos A, Wass JA, Trainer PJ; ERCUSYN Study Group.

Eur J Endocrinol. 2017 May;176(5):613-624. doi: 10.1530/EJE-16-0967.

PMID:
28377460
11.

Hyponatraemia secondary to nivolumab-induced primary adrenal failure.

Trainer H, Hulse P, Higham CE, Trainer P, Lorigan P.

Endocrinol Diabetes Metab Case Rep. 2016;2016. pii: 16-0108. Epub 2016 Nov 1.

12.

A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.

Drake WM, Stiles CE, Bevan JS, Karavitaki N, Trainer PJ, Rees DA, Richardson TI, Baldeweg SE, Stojanovic N, Murray RD, Toogood AA, Martin NM, Vaidya B, Han TS, Steeds RP; UK Cabergoline valvulopathy study group, Baldeweg FC, Sheikh UE, Kyriakakis N, Parasuraman SK, Taylor L, Butt N, Anyiam S.

J Clin Endocrinol Metab. 2016 Nov;101(11):4189-4194. Epub 2016 Aug 29.

PMID:
27571182
13.

Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity - data from the EU-AIR.

Murray RD, Ekman B, Uddin S, Marelli C, Quinkler M, Zelissen PM; the EU-AIR Investigators.

Clin Endocrinol (Oxf). 2017 Mar;86(3):340-346. doi: 10.1111/cen.13267. Epub 2016 Dec 5.

14.

Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.

Strasburger CJ, Karavitaki N, Störmann S, Trainer PJ, Kreitschmann-Andermahr I, Droste M, Korbonits M, Feldmann B, Zopf K, Sanderson VF, Schwicker D, Gelbaum D, Haviv A, Bidlingmaier M, Biermasz NR.

Eur J Endocrinol. 2016 Mar;174(3):355-62. doi: 10.1530/EJE-15-1042. Epub 2015 Dec 18.

15.

Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement.

Adaway JE, Dobson R, Walsh J, Cuthbertson DJ, Monaghan PJ, Trainer PJ, Valle JW, Keevil BG.

Ann Clin Biochem. 2016 Sep;53(Pt 5):554-60. doi: 10.1177/0004563215613109. Epub 2015 Oct 5.

PMID:
26438520
16.

Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.

Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, Boelaert K, Chortis V, Cuthbertson DJ, Daousi C, Rajeev SP, Davis J, Cheer K, Drake W, Gunganah K, Grossman A, Gurnell M, Powlson AS, Karavitaki N, Huguet I, Kearney T, Mohit K, Meeran K, Hill N, Rees A, Lansdown AJ, Trainer PJ, Minder AE, Newell-Price J.

J Clin Endocrinol Metab. 2015 Nov;100(11):4146-54. doi: 10.1210/jc.2015-2616. Epub 2015 Sep 9.

17.

Intractable hypoglycaemia in a patient with advanced carcinoid syndrome successfully treated with hepatic embolization.

Kyriacou A, Mansoor W, Lawrance J, Trainer PJ.

Hormones (Athens). 2016 Jan-Mar;15(1):118-21. doi: 10.14310/horm.2002.1607.

18.

Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers.

Hernández-Ramírez LC, Gabrovska P, Dénes J, Stals K, Trivellin G, Tilley D, Ferrau F, Evanson J, Ellard S, Grossman AB, Roncaroli F, Gadelha MR, Korbonits M; International FIPA Consortium.

J Clin Endocrinol Metab. 2015 Sep;100(9):E1242-54.

19.

Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial.

Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, Glaser B, Goth M, Greenman Y, Trainer P, Mezosi E, Shimon I, Giustina A, Korbonits M, Bronstein MD, Kleinberg D, Teichman S, Gliko-Kabir I, Mamluk R, Haviv A, Strasburger C.

J Clin Endocrinol Metab. 2015 Apr;100(4):1699-708. doi: 10.1210/jc.2014-4113. Epub 2015 Feb 9. Erratum in: J Clin Endocrinol Metab. 2016 Oct;101(10 ):3863.

PMID:
25664604
20.

Case for the wider adoption of mass spectrometry-based adrenal steroid testing, and beyond.

Monaghan PJ, Keevil BG, Stewart PM, Trainer PJ.

J Clin Endocrinol Metab. 2014 Dec;99(12):4434-7. doi: 10.1210/jc.2014-2258. No abstract available.

PMID:
25322267
21.

Evaluation of pituitary function.

Cheer K, Trainer PJ.

Handb Clin Neurol. 2014;124:141-9. doi: 10.1016/B978-0-444-59602-4.00010-1. Review.

PMID:
25248585
22.

Next generation medical therapy for Cushing's syndrome--can we measure a benefit?

Trainer PJ.

J Clin Endocrinol Metab. 2014 Apr;99(4):1157-60. doi: 10.1210/jc.2014-1054. No abstract available.

PMID:
24702012
23.

The harmonisation of growth hormone measurements: taking the next steps.

Wieringa GE, Sturgeon CM, Trainer PJ.

Clin Chim Acta. 2014 May 15;432:68-71. doi: 10.1016/j.cca.2014.01.014. Epub 2014 Feb 6. Review.

PMID:
24509000
24.

New options for the medical treatment of Cushing's syndrome.

Trainer PJ.

Indian J Endocrinol Metab. 2013 Mar;17(2):245-8. doi: 10.4103/2230-8210.109685.

25.

Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.

Howlett TA, Willis D, Walker G, Wass JA, Trainer PJ; UK Acromegaly Register Study Group (UKAR-3).

Clin Endocrinol (Oxf). 2013 Nov;79(5):689-99. doi: 10.1111/cen.12207. Epub 2013 Apr 24.

PMID:
23574573
26.

The use of mass spectrometry to improve the diagnosis and the management of the HPA axis.

Monaghan PJ, Keevil BG, Trainer PJ.

Rev Endocr Metab Disord. 2013 Jun;14(2):143-57. doi: 10.1007/s11154-013-9240-1. Review.

PMID:
23494459
27.

Mass spectrometry for the endocrine clinic--much to digest.

Monaghan PJ, Keevil BG, Trainer PJ.

Clin Endocrinol (Oxf). 2013 Mar;78(3):344-6. doi: 10.1111/cen.12125. No abstract available.

PMID:
23231746
28.

Regulation of cortisol bioavailability--effects on hormone measurement and action.

Perogamvros I, Ray DW, Trainer PJ.

Nat Rev Endocrinol. 2012 Dec;8(12):717-27. doi: 10.1038/nrendo.2012.134. Epub 2012 Aug 14. Review.

PMID:
22890008
29.

Acromegaly surgery in Manchester revisited--the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission.

Wang YY, Higham C, Kearney T, Davis JR, Trainer P, Gnanalingham KK.

Clin Endocrinol (Oxf). 2012 Mar;76(3):399-406. doi: 10.1111/j.1365-2265.2011.04193.x.

PMID:
21824170
30.

Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone.

Monaghan PJ, Owen LJ, Trainer PJ, Brabant G, Keevil BG, Darby D.

Ann Clin Biochem. 2011 Sep;48(Pt 5):441-6. doi: 10.1258/acb.2011.011014. Epub 2011 Aug 3.

PMID:
21813575
31.

Lessons learned from 15 years of KIMS and 5 years of ACROSTUDY.

Luger A, Feldt-Rasmussen U, Abs R, Gaillard RC, Buchfelder M, Trainer P, Brue T.

Horm Res Paediatr. 2011;76 Suppl 1:33-8. doi: 10.1159/000329156. Epub 2011 Jul 21.

PMID:
21778746
32.

The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics.

Valassi E, Santos A, Yaneva M, Tóth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA, Tsagarakis S, Trainer PJ, Franz H, Zopf K, Zacharieva S, Lamberts SW, Tabarin A, Webb SM; ERCUSYN Study Group.

Eur J Endocrinol. 2011 Sep;165(3):383-92. doi: 10.1530/EJE-11-0272. Epub 2011 Jun 29.

PMID:
21715416
33.

Early diagnosis of acromegaly: computers vs clinicians.

Miller RE, Learned-Miller EG, Trainer P, Paisley A, Blanz V.

Clin Endocrinol (Oxf). 2011 Aug;75(2):226-31. doi: 10.1111/j.1365-2265.2011.04020.x.

PMID:
21521289
34.

Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve.

Leach P, Abou-Zeid AH, Kearney T, Davis J, Trainer PJ, Gnanalingham KK.

Neurosurgery. 2010 Nov;67(5):1205-12. doi: 10.1227/NEU.0b013e3181ef25c5.

PMID:
20871457
35.

Spuriously Elevated Serum IGF-1 in Adult Individuals with Delayed Puberty: A Diagnostic Pitfall.

Imran SA, Pelkey M, Clarke DB, Clayton D, Trainer P, Ezzat S.

Int J Endocrinol. 2010;2010. pii: 370692. doi: 10.1155/2010/370692. Epub 2010 Aug 30.

36.

The pituitary gland and age-dependent regulation of body composition.

van Beek AP, Wolffenbuttel BH, Runge E, Trainer PJ, Jönsson PJ, Koltowska-Häggström M.

J Clin Endocrinol Metab. 2010 Aug;95(8):3664-74. doi: 10.1210/jc.2009-2506. Epub 2010 May 19.

PMID:
20484487
37.

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM; Pasireotide Acromegaly Study Group.

J Clin Endocrinol Metab. 2010 Jun;95(6):2781-9. doi: 10.1210/jc.2009-2272. Epub 2010 Apr 21.

PMID:
20410233
38.

Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease.

Höybye C, Ragnarsson O, Jönsson PJ, Koltowska-Häggström M, Trainer P, Feldt-Rasmussen U, Biller BM.

Eur J Endocrinol. 2010 Apr;162(4):677-84. doi: 10.1530/EJE-09-0836. Epub 2010 Jan 20.

PMID:
20089548
39.

Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: application in basal and stimulated conditions.

Perogamvros I, Owen LJ, Newell-Price J, Ray DW, Trainer PJ, Keevil BG.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3771-5. doi: 10.1016/j.jchromb.2009.09.014. Epub 2009 Sep 18.

PMID:
19783236
40.

Giant leaps forward.

Trainer P.

Clin Med (Lond). 2009 Aug;9(4):363-4. Review. No abstract available.

PMID:
19728514
41.

ACROSTUDY: the first 5 years.

Trainer PJ.

Eur J Endocrinol. 2009 Nov;161 Suppl 1:S19-24. doi: 10.1530/EJE-09-0322. Epub 2009 Aug 14.

PMID:
19684052
42.

Expanding the spectrum of mutations in GH1 and GHRHR: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency.

Alatzoglou KS, Turton JP, Kelberman D, Clayton PE, Mehta A, Buchanan C, Aylwin S, Crowne EC, Christesen HT, Hertel NT, Trainer PJ, Savage MO, Raza J, Banerjee K, Sinha SK, Ten S, Mushtaq T, Brauner R, Cheetham TD, Hindmarsh PC, Mullis PE, Dattani MT.

J Clin Endocrinol Metab. 2009 Sep;94(9):3191-9. doi: 10.1210/jc.2008-2783. Epub 2009 Jun 30.

PMID:
19567534
43.

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.

Trainer PJ, Ezzat S, D'Souza GA, Layton G, Strasburger CJ.

Clin Endocrinol (Oxf). 2009 Oct;71(4):549-57. doi: 10.1111/j.1365-2265.2009.03620.x. Epub 2009 May 2.

PMID:
19438906
44.

Measurement of salivary cortisol with liquid chromatography-tandem mass spectrometry in patients undergoing dynamic endocrine testing.

Perogamvros I, Owen LJ, Keevil BG, Brabant G, Trainer PJ.

Clin Endocrinol (Oxf). 2010 Jan;72(1):17-21. doi: 10.1111/j.1365-2265.2009.03582.x. Epub 2009 Mar 19.

PMID:
19302583
45.

The cardiovascular phenotype of a mouse model of acromegaly.

Izzard AS, Emerson M, Prehar S, Neyses L, Trainer P, List EO, Kopchick JJ, Heagerty AM.

Growth Horm IGF Res. 2009 Oct;19(5):413-9. doi: 10.1016/j.ghir.2008.12.006. Epub 2009 Mar 9.

PMID:
19269870
46.

Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly.

Paisley AN, Izzard AS, Gemmell I, Cruickshank K, Trainer PJ, Heagerty AM.

J Clin Endocrinol Metab. 2009 Apr;94(4):1111-7. doi: 10.1210/jc.2008-0948. Epub 2009 Jan 27.

PMID:
19174501
47.

Pituitary-independent effect of octreotide on IGF1 generation.

Pokrajac A, Frystyk J, Flyvbjerg A, Trainer PJ.

Eur J Endocrinol. 2009 Apr;160(4):543-8. doi: 10.1530/EJE-08-0822. Epub 2009 Jan 13.

PMID:
19141605
48.

Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials.

Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ, Gagel RF.

Eur J Endocrinol. 2008 Nov;159(5):517-23. doi: 10.1530/EJE-08-0205. Epub 2008 Aug 15.

PMID:
18708436
49.

ACROSTUDY: an overview.

Trainer PJ.

Horm Res. 2007;68 Suppl 5:68-9. doi: 10.1159/000110480. Epub 2007 Dec 10. No abstract available.

PMID:
18174712
50.

Pharmacological management of Cushing's syndrome: an update.

Dang CN, Trainer P.

Arq Bras Endocrinol Metabol. 2007 Nov;51(8):1339-48.

Supplemental Content

Loading ...
Support Center